Frick E, Stickl H
J Neurol Sci. 1980 May;46(2):187-97. doi: 10.1016/0022-510x(80)90077-5.
An antibody was demonstrated in the serum of 166 out of 200 patients with MS which enabled normal lymphocytes to develop a cytotoxic (ADLC) reaction against MBP. The ADLC correlated with the stage of the process and was positive in 94% of those with active and in 62% of those with inactive disease independent of the type--relapsing or chronic progressive--and of the severity of the disease. Control studies in 200 patients with other organic nervous complaints gave positive findings in patients with carcinoma (7.5%), in rheumatoid arthritis (10-15%) and in syphilis (30%). On the ground of its good specificity and the frequency of positive findings, the reaction may be of diagnostic significance. In 55 of 57 CSF samples investigated in MS, the ADLC was positive. The intensity of the cytotoxicity in serum and CSF is practically identical. This finding supports the pathogenetic significance of the ADLC against MBP although it has no validity as a primary aetiological factor.
在200例多发性硬化症患者中,有166例患者血清中检测到一种抗体,该抗体能使正常淋巴细胞对髓鞘碱性蛋白(MBP)产生细胞毒性(抗体依赖淋巴细胞介导的细胞毒性,ADLC)反应。ADLC与疾病进程阶段相关,在94%的活动期患者和62%的非活动期患者中呈阳性,与疾病类型(复发型或慢性进展型)及疾病严重程度无关。对200例患有其他器质性神经疾病的患者进行对照研究发现,癌症患者(7.5%)、类风湿性关节炎患者(10 - 15%)和梅毒患者(30%)中也有阳性结果。基于其良好的特异性和较高的阳性检出率,该反应可能具有诊断意义。在对57例多发性硬化症患者的脑脊液样本进行检测时,其中55例ADLC呈阳性。血清和脑脊液中细胞毒性的强度实际上是相同的。这一发现支持了针对MBP的ADLC在发病机制中的重要性,尽管它作为主要病因因素并不成立。